Get started
Agenus Inc.Agenus Inc.Agenus Inc.

Agenus Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

AGEN trade ideas

AGEN reverse split pumpA reverse split pump in the small cap stock market refers to a situation where a company, typically with a low stock price, undergoes a reverse stock split in order to artificially inflate its stock price. Here's how it typically works: Low Stock Price: Small cap stocks often have low prices per share, sometimes trading for just a few cents. This low price can make the stock less attractive to investors and may even lead to delisting from stock exchanges that have minimum price requirements. Reverse Stock Split: To combat the low stock price and possibly meet exchange listing requirements, the company executes a reverse stock split. In a reverse split, existing shares are combined to reduce the total number of outstanding shares, thereby increasing the price per share proportionally. For example, in a 1-for-10 reverse split, every 10 shares a shareholder owns are converted into 1 share, effectively increasing the price by a factor of 10. Pump: After the reverse split, there may be efforts to artificially boost the stock price, creating what is known as a "pump." This can involve various tactics, such as promotional campaigns, exaggerated press releases, or even coordinated buying by groups of investors. The goal is to create a perception of increased value and generate buying interest in the stock.
NASDAQ:AGENLong
by AntonioNaVi
AGEN - LONGAGEN, a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Biopharma Conference on March 11th - 13th in Miami Beach, Florida. The fireside chat will take place at 2:30 p.m. ET on March 11th. What are they working on?: Agenus is focusing on immuno-oncology, conducting Phase 2 trials with botensilimab in melanoma, MSS colorectal cancer (with balstilimab), and pancreatic cancer (with chemotherapy). They're also developing balstilimab, a PD-1 inhibitor, across various cancers, including cervical cancer in Phase 2 trials. AGEN2373, an anti-CD137 agonist, is in Phase 1 trials for solid tumors, showcasing Agenus's commitment to advancing cancer treatments through innovative therapies​ POSSIBLE SELL CLIMAX HERE. If we break below, I will look for another Buy opportunity at the .63 area.
NASDAQ:AGENLong
by SPYDERMARKET
AGENUS Stock Chart Fibonacci Analysis 071023 Trading Idea 1) Find a FIBO slingshot 2) Check FIBO 61.80% level 3) Entry Point > 1.7/61.80% Chart time frame : B A) 15 min(1W-3M) B) 1 hr(3M-6M) C) 4 hr(6M-1year) D) 1 day(1-3years) Stock progress : A A) Keep rising over 61.80% resistance B) 61.80% resistance C) Hit the bottom D) Hit the top Stocks rise as they rise from support and fall from resistance. Our goal is to find a low support point and enter. It can be referred to as buying at the pullback point. The pullback point can be found with a Fibonacci extension of 61.80%. This is a step to find entry level. 1) Find a triangle (Fibonacci Speed Fan Line) that connects the high (resistance) and low (support) points of the stock in progress, where it is continuously expressed as a Slingshot, 2) and create a Fibonacci extension level for the first rising wave from the start point of slingshot pattern. When the current price goes over 61.80% level , that can be a good entry point, especially if the SMA 100 and 200 curves are gathered together at 61.80%, it is a very good entry point. As a great help, tradingview provide these Fibonacci speed fan lines and extension levels with ease. So if you use the Fibonacci fan line, the extension level, and the SMA 100/200 curve well, you can find an entry point for the stock market. At least you have to enter at this low point to avoid trading failure, and if you are skilled at entering this low point, with fibonacci6180 technique, your reading skill to chart will be greatly improved. If you want to do day trading, please set the time frame to 5 minutes or 15 minutes, and you will see many of the low point of rising stocks. If want to prefer long term range trading, you can set the time frame to 1 hr or 1 day.
NASDAQ:AGEN
by fibonacci6180
AGEN Daily TimeframeSNIPER STRATEGY (new version) It works ALMOST ON ANY CHART. It produces Weak, Medium and Strong signals based on consisting elements. NOT ALL TARGETS CAN BE ACHIEVED, let's make that clear. TARGETS OR ENTRY PRICES ARE STRONG SUPPORT AND RESISTANCE LEVELS. ENTRY PRICE BLACK COLOR TARGETS GREEN COLOR STOP LOSS RED COLOR DO NOT USE THIS STROTEGY FOR LEVERAGED TRADING. It will not give you the whole wave like any other strategy out there but it will give you a huge part of the wave. The BEST TIMEFRAMES for this strategy are Daily, Weekly and Monthly however it can work on any timeframe. Consider those points and you will have a huge advantage in the market. There is a lot more about this strategy. It can predict possible target and also give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts. START BELIEVING AND GOOD LUCK HADIMOZAYAN
NASDAQ:AGENShort
by hadimozayan
AGEN digging through the CratesAGEN hasn't done this in years...what? It hasn't sustained these levels for any meaningful amount of time. I did a quick fib retracement using those 2017 highs as the upper anchor and you can see what has revealed itself. The 236 area is a key pivot. Most of the time it has acted as a resistance pivot. But, so far AGEN has held these levels. Where does it go from here? A lot of that might have to do with what's coming. " pipeline treatments like AGEN1777 have gained interest from some of the industry’s leading names. Bristol Myers Squibb ( BMY ) has a global exclusive license with Agenus providing up to $200 million in cash upfront. The company can also receive up to $1.36 billion if it reaches specific milestones and includes royalties upon any sales. The FDA already cleared an Investigational New Drug Application for a Phase 1 dosing with AGEN1777 alone and combined with an anti-PD-1 in solid tumors. That’s expected to begin this quarter...Balstilimab...is something that could be in focus as well. The FDA accepted a Biologics License Application for priority review. A Prescription Drug User Fee Act (PDUFA) target date was also given. December 16th will be the PDUFA date and could present an important one for the company and Balstilimab. Phase 2 data showed a response rate of 20% in PD-L1 positive tumors, an overall response rate of 15%, and a median duration of response of 15.4 months. Furthermore, Phase 2 trial results of balstilimab combined with zalifrelimab (AGEN1884) will be presented at a Mini Oral Session at the European Society for Medical Oncology Congress next month. So plenty to watch if AGEN stock is on your watch list right now. " Quote Source & Read more On AGEN: Hot Biotech Stocks That Deserve Your Attention In August 2021
NASDAQ:AGEN
by PennyStocks101
High Traffic Resistance & Upcoming CatalystThis week will be a potentially big one (in either direction for AGEN imo and it will come down to the data to tell which way the stock breaks...or breaks down. This week, AGEN stock could be on the list of penny stocks to watch. Two posters will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting from June 4 – 8, 2021.The focus will likely be on the specifics of the trial and its design. “We are encouraged by the differentiated qualities of our anti-PD-1 balstilimab both in the clinic and in preclinical…Our novel CD137, AGEN2373, has been well-tolerated in this dose-escalation trial, and we look forward to advancing it into combinations for potential benefit to patients,” said Steven O’Day, MD, Chief Medical Officer at Agenus, in a PR last week. Quote Source: Hot Penny Stocks To Buy On Robinhood With Upcoming Events This Week
NASDAQ:AGEN
by PennyStocks101
AGENUS INC*Investment opportunity - low risk* The summary below is the result of hours of study - I go to sleep and dream of charts, and not by choice! If you find this idea of value please like and share. On the above monthly chart price action has been in a downtrend for 20 years to the day. A number of technical indicators and three oversold conditions (orange columns) now makes Agenus (AGEN) an exciting stock to add to your portfolio. Lets go through them: 1) I’m quite certain no one is looking at this. The Blue resistance trend line has continued to act as resistance for 20 years. The 2-month chart below provides a clearer picture. At the end of 2020 price action closed a 2-month candle above that resistance. This is extraordinarily bullish. Make no mistake how powerful an indication this is. 2) On the monthly chart price action closed a monthly candle on the 200-week simple moving average (red line). It has been six years since that happened. 3) Volume. Leading up to the resistance breakout volume was increasing and continues to do so. 4) Stochastic RSI on the monthly is crossing up (circled in orange) whilst making a higher low. All together the chart is telling me serious upside is in the post. A buy from $3.30 is excellent. 1st target is $14 2-month chart
NASDAQ:AGENLong
by without_worries
$AGEN Presents Trial Results This WeekendFundamental Analysis: Agenus Inc. is an immuno-oncology company that develops technologies to treat cancers and other infectious diseases. One drug that they are developing, AGEN1181 , has undergone phase 1/2 safety trials. The results from these trials were released on February 9, 2021, and the results will be presented at AACR on April 10, 2021. AGEN1181 is a colon cancer treatment and this is likely to attract many buyers. Technical Analysis: $AGEN recently broke its downtrend resistance line and has seen strong growth since. The MACD just crossed as well. We could see a sharp rebound in the price this week. My Outlook: I am anticipating at least $3.80 by the end of the week. We are seeing strong growth coming off of a large dip, and people are likely to get excited when they see that this is a cancer treatment. Playing the post-release is an option here as well since the price is very low and it is only in phase 1/2. However, because it is early in the development of this drug, the price will likely pop and then tank steadily the week after the release. If you plan on waiting for the presentation before selling, I would recommend selling at the market open next Monday for optimal gains. Like and Follow :) Good Luck! If you like these biotech ideas, follow @CobraTrader13 for weekly biotech watchlists.
NASDAQ:AGENLong
by Investor4321